Skip to main content
. 2011 Jul 29;118(17):4541–4546. doi: 10.1182/blood-2011-04-348110

Table 3.

Outcome

3-month CCyR
6-month CCyR
12-month CCyR
Yes No P Yes No P Yes No P
Total group
    3-year EFS 98 83 < .001 97 72 < .001 98 67 < .001
    3-year OS 99 95 .06 99 90 < .001 99 94 < .001
IM 400 mg
    3-year EFS 92 81 .12 97 74 .001 98 72 < .001
    3-year OS 100 88 .046 100 87 .09 100 88 .046
IM 800 mg
    3-year EFS 97 84 .005 97 68 < .001 98 58 < .001
    3-year OS 98 97 .93 99 92 .001 99 100 .03
Second TKI
    3-year EFS 100 80 < .001 99 67 < .001 99 NA NA
    3-year OS 100 100 NA 100 100 NA 100 NA NA
P (EFS/OS) .07/.3 .56/.81 .9/.6

IM indicates imatinib; and NA, not applicable